Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 654

1.

Novel molecular targets for the treatment of lung cancer.

Rosell R, Karachaliou N, Arrieta O.

Curr Opin Oncol. 2019 Oct 9. doi: 10.1097/CCO.0000000000000590. [Epub ahead of print]

PMID:
31599770
2.

Are neutralising anti-VEGF or VEGFR2 antibodies necessary in the treatment of EGFR-mutated non-small-cell lung cancer?

Rosell R, Pedraz-Valdunciel C.

Lancet Oncol. 2019 Oct 4. pii: S1470-2045(19)30636-9. doi: 10.1016/S1470-2045(19)30636-9. [Epub ahead of print] No abstract available.

PMID:
31591061
3.

Lung cavitation in lung metastases of gastric and non-small-cell lung cancer patients treated with apatinib.

Cecere FL, Aguilar A, Rosell R.

Transl Lung Cancer Res. 2019 Aug;8(4):317-318. doi: 10.21037/tlcr.2019.08.20. No abstract available.

4.

Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines.

Codony-Servat J, Viteri S, Codony-Servat C, Ito M, Bracht JWP, Berenguer J, Chaib I, Molina-Vila MA, Karachaliou N, Rosell R.

Transl Lung Cancer Res. 2019 Aug;8(4):340-351. doi: 10.21037/tlcr.2019.08.22.

5.

BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale.

Bracht JWP, Karachaliou N, Bivona T, Lanman RB, Faull I, Nagy RJ, Drozdowskyj A, Berenguer J, Fernandez-Bruno M, Molina-Vila MA, Rosell R.

Cancers (Basel). 2019 Sep 17;11(9). pii: E1381. doi: 10.3390/cancers11091381.

6.

Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions.

Villatoro S, Mayo-de-Las-Casas C, Jordana-Ariza N, Viteri-Ramírez S, Garzón-Ibañez M, Moya-Horno I, García-Peláez B, González-Cao M, Malapelle U, Balada-Bel A, Martínez-Bueno A, Campos R, Reguart N, Majem M, Blanco R, Blasco A, Catalán MJ, González X, Troncone G, Karachaliou N, Rosell R, Molina-Vila MA.

Mol Oncol. 2019 Sep 17. doi: 10.1002/1878-0261.12574. [Epub ahead of print]

7.

Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Phase 2 Randomized Clinical Trial.

Arrieta O, Barrón F, Padilla MS, Avilés-Salas A, Ramírez-Tirado LA, Arguelles Jiménez MJ, Vergara E, Zatarain-Barrón ZL, Hernández-Pedro N, Cardona AF, Cruz-Rico G, Barrios-Bernal P, Yamamoto Ramos M, Rosell R.

JAMA Oncol. 2019 Sep 5:e192553. doi: 10.1001/jamaoncol.2019.2553. [Epub ahead of print]

PMID:
31486833
8.

Characterising acquired resistance to erlotinib in non-small cell lung cancer patients.

Karachaliou N, Codony-Servat J, Bracht JWP, Ito M, Filipska M, Pedraz C, Chaib I, Bertran-Alamillo J, Cardona AF, Molina MA, Rosell R.

Expert Rev Respir Med. 2019 Oct;13(10):1019-1028. doi: 10.1080/17476348.2019.1656068. Epub 2019 Aug 19.

PMID:
31411906
9.

PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around.

Gkountakos A, Sartori G, Falcone I, Piro G, Ciuffreda L, Carbone C, Tortora G, Scarpa A, Bria E, Milella M, Rosell R, Corbo V, Pilotto S.

Cancers (Basel). 2019 Aug 9;11(8). pii: E1141. doi: 10.3390/cancers11081141. Review.

10.

Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer.

Santarpia M, Menis J, Chaib I, Gonzalez Cao M, Rosell R.

Expert Rev Clin Pharmacol. 2019 Sep;12(9):831-840. doi: 10.1080/17512433.2019.1649136. Epub 2019 Aug 5. Review.

PMID:
31356117
11.

Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives.

Karachaliou N, Fernandez Bruno M, Bracht JWP, Rosell R.

Onco Targets Ther. 2019 Jun 13;12:4567-4575. doi: 10.2147/OTT.S174548. eCollection 2019. Review.

12.

Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer.

Corral J, Mok TS, Nakagawa K, Rosell R, Lee KH, Migliorino MR, Pluzanski A, Linke R, Devgan G, Tan W, Quinn S, Wang T, Wu YL.

Future Oncol. 2019 Aug;15(24):2795-2805. doi: 10.2217/fon-2019-0299. Epub 2019 Jul 17.

13.

Investigation of chronic and persistent classical swine fever infections under field conditions and their impact on vaccine efficacy.

Coronado L, Bohórquez JA, Muñoz-González S, Perez LJ, Rosell R, Fonseca O, Delgado L, Perera CL, Frías MT, Ganges L.

BMC Vet Res. 2019 Jul 15;15(1):247. doi: 10.1186/s12917-019-1982-x.

14.

Assessing lake ecological status across a trophic gradient through environmental and biological variables.

Macintosh KA, Cromie H, Forasacco E, Gallagher K, Kelly FL, McElarney Y, O'Kane E, Paul A, Rippey B, Rosell R, Vaughan L, Ward C, Griffiths D.

Sci Total Environ. 2019 Nov 10;690:831-840. doi: 10.1016/j.scitotenv.2019.07.038. Epub 2019 Jul 4.

PMID:
31302548
15.

Salvage surgery after definitive chemo-radiotherapy for patients with Non-Small Cell Lung Cancer.

Romero-Vielva L, Viteri S, Moya-Horno I, Toscas JI, Maestre-Alcácer JA, Ramón Y Cajal S, Rosell R.

Lung Cancer. 2019 Jul;133:117-122. doi: 10.1016/j.lungcan.2019.05.010. Epub 2019 May 13.

PMID:
31200817
16.

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.

Mazières J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, Van Den Heuvel M, Neal J, Peled N, Früh M, Ng TL, Gounant V, Popat S, Diebold J, Sabari J, Zhu VW, Rothschild SI, Bironzo P, Martinez A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten RD, Wakelee H, Camidge DR, Zalcman G, Novello S, Ou SI, Milia J, Gautschi O.

Ann Oncol. 2019 May 24. pii: mdz167. doi: 10.1093/annonc/mdz167. [Epub ahead of print]

PMID:
31125062
17.

Pharmacokinetics of isoniazid: The good, the bad, and the alternatives.

Erwin ER, Addison AP, John SF, Olaleye OA, Rosell RC.

Tuberculosis (Edinb). 2019 May;116S:S66-S70. doi: 10.1016/j.tube.2019.04.012. Epub 2019 Apr 26.

PMID:
31076322
18.

Correction: Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer.

Morán T, Felip E, Bosch-Barrera J, de Aguirre I, Ramirez JL, Mesia C, Carcereny E, Roa D, Sais E, García Y, Blanco R, Sanchez S, Villacorta CR, Queralt C, Velarde JM, Rosell R.

Oncotarget. 2019 Apr 2;10(26):2576. doi: 10.18632/oncotarget.26855. eCollection 2019 Apr 2.

19.

Multigene Mutation Profiling and Clinical Characteristics of Small-Cell Lung Cancer in Never-Smokers vs. Heavy Smokers (Geno1.3-CLICaP).

Cardona AF, Rojas L, Zatarain-Barrón ZL, Ruiz-Patiño A, Ricaurte L, Corrales L, Martín C, Freitas H, Cordeiro de Lima VC, Rodriguez J, Avila J, Bravo M, Archila P, Carranza H, Vargas C, Otero J, Barrón F, Karachaliou N, Rosell R, Arrieta O.

Front Oncol. 2019 Apr 17;9:254. doi: 10.3389/fonc.2019.00254. eCollection 2019.

20.

Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens.

Pisapia P, Malapelle U, Roma G, Saddar S, Zheng Q, Pepe F, Bruzzese D, Vigliar E, Bellevicine C, Luthra R, Nikiforov YE, Mayo-de-Las-Casas C, Molina-Vila MA, Rosell R, Bihl M, Savic S, Bubendorf L, de Biase D, Tallini G, Hwang DH, Sholl LM, Vander Borght S, Weynand B, Stieber D, Vielh P, Rappa A, Barberis M, Fassan M, Rugge M, De Andrea CE, Lozano MD, Lupi C, Fontanini G, Schmitt F, Dumur CI, Bisig B, Bongiovanni M, Merkelbach-Bruse S, Büttner R, Nikiforova MN, Roy-Chowdhuri S, Troncone G; Molecular Cytopathology Meeting Group.

Cancer Cytopathol. 2019 May;127(5):285-296. doi: 10.1002/cncy.22134. Epub 2019 Apr 25.

PMID:
31021538
21.

AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy.

Bertran-Alamillo J, Cattan V, Schoumacher M, Codony-Servat J, Giménez-Capitán A, Cantero F, Burbridge M, Rodríguez S, Teixidó C, Roman R, Castellví J, García-Román S, Codony-Servat C, Viteri S, Cardona AF, Karachaliou N, Rosell R, Molina-Vila MA.

Nat Commun. 2019 Apr 18;10(1):1812. doi: 10.1038/s41467-019-09734-5.

22.

Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.

Michels S, Massutí B, Schildhaus HU, Franklin J, Sebastian M, Felip E, Grohé C, Rodriguez-Abreu D, Abdulla DSY, Bischoff H, Brandts C, Carcereny E, Corral J, Dingemans AC, Pereira E, Fassunke J, Fischer RN, Gardizi M, Heukamp L, Insa A, Kron A, Menon R, Persigehl T, Reck M, Riedel R, Rothschild SI, Scheel AH, Scheffler M, Schmalz P, Smit EF, Limburg M, Provencio M, Karachaliou N, Merkelbach-Bruse S, Hellmich M, Nogova L, Büttner R, Rosell R, Wolf J.

J Thorac Oncol. 2019 Jul;14(7):1266-1276. doi: 10.1016/j.jtho.2019.03.020. Epub 2019 Apr 9.

PMID:
30978502
23.

Experimental infection with high- and low-virulence strains of border disease virus (BDV) in Pyrenean chamois (Rupicapra p. pyrenaica) sheds light on the epidemiological diversity of the disease.

Colom-Cadena A, Marco I, Fernández Aguilar X, Velarde R, Espunyes J, Rosell R, Lavín S, Cabezón O.

Transbound Emerg Dis. 2019 Jul;66(4):1619-1630. doi: 10.1111/tbed.13195. Epub 2019 Apr 29.

PMID:
30963719
24.

Disulfide isomerase family-6 mediates cisplatin resistance by interfering with apoptosis and autophagy.

Rosell R, Karachaliou N.

EBioMedicine. 2019 Apr;42:20-21. doi: 10.1016/j.ebiom.2019.03.088. Epub 2019 Apr 5. No abstract available.

25.

Co-mutations in EGFR driven non-small cell lung cancer.

Rosell R, Karachaliou N.

EBioMedicine. 2019 Apr;42:18-19. doi: 10.1016/j.ebiom.2019.03.037. Epub 2019 Mar 20. No abstract available.

26.

Cancer Stem Cell Biomarkers in EGFR-Mutation-Positive Non-Small-Cell Lung Cancer.

Codony-Servat J, Codony-Servat C, Cardona AF, Giménez-Capitán A, Drozdowskyj A, Berenguer J, Bracht JWP, Ito M, Karachaliou N, Rosell R.

Clin Lung Cancer. 2019 May;20(3):167-177. doi: 10.1016/j.cllc.2019.02.005. Epub 2019 Feb 21.

PMID:
30885551
27.

Association between the novel classification of lung adenocarcinoma subtypes and EGFR/KRAS mutation status: A systematic literature review and pooled-data analysis.

Jiang L, Mino-Kenudson M, Roden AC, Rosell R, Molina MÁ, Flores RM, Pilz LR, Brunelli A, Venuta F, He J; AME Lung Cancer Collaborative Group.

Eur J Surg Oncol. 2019 May;45(5):870-876. doi: 10.1016/j.ejso.2019.02.006. Epub 2019 Feb 16.

PMID:
30833014
28.

A Single-Center Retrospective Study of Patients with Double Primary Cancers: Breast Cancer and EGFR-Mutant Non-Small Cell Lung Cancer.

Moran T, Quiroga V, Cirauqui B, Vila L, Gil-Moreno M, Carcereny E, Margeli M, Muñoz-Marmol A, Mate JL, Velarde JM, Molina MA, Rosell R.

Oncol Res Treat. 2019;42(3):107-114. doi: 10.1159/000495666. Epub 2019 Feb 23.

PMID:
30799393
29.

A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma.

Cardona AF, Rojas L, Wills B, Ruiz-Patiño A, Abril L, Hakim F, Jiménez E, Useche N, Bermúdez S, Mejía JA, Ramón JF, Carranza H, Vargas C, Otero J, Archila P, Rodríguez J, Rodríguez J, Behaine J, González D, Jacobo J, Cifuentes H, Feo O, Penagos P, Pineda D, Ricaurte L, Pino LE, Vargas C, Marquez JC, Mantilla MI, Ortiz LD, Balaña C, Rosell R, Zatarain-Barrón ZL, Arrieta O.

Clin Transl Oncol. 2019 Oct;21(10):1364-1373. doi: 10.1007/s12094-019-02066-2. Epub 2019 Feb 23.

PMID:
30798512
30.

Evaluation of the effectiveness of the SurePure Turbulator ultraviolet-C irradiation equipment on inactivation of different enveloped and non-enveloped viruses inoculated in commercially collected liquid animal plasma.

Blázquez E, Rodríguez C, Ródenas J, Navarro N, Riquelme C, Rosell R, Campbell J, Crenshaw J, Segalés J, Pujols J, Polo J.

PLoS One. 2019 Feb 21;14(2):e0212332. doi: 10.1371/journal.pone.0212332. eCollection 2019.

31.

Biological therapies in lung cancer treatment: using our immune system as an ally to defeat the malignancy.

Filipska M, Pedraz-Valdunciel C, Chaib I, Rosell R.

Expert Opin Biol Ther. 2019 May;19(5):457-467. doi: 10.1080/14712598.2019.1582635. Epub 2019 Feb 27.

PMID:
30763126
32.

Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP).

Rojas L, Cardona AF, Trejo-Rosales R, Zatarain-Barrón ZL, Ramírez-Tirado LA, Ruiz-Patiño A, Campos Gómez S, Corrales L, Oblitas G, Bacon L, Martín C, de Lima VCC, Freitas HC, Mas L, Vargas C, Carranza H, Otero J, Pérez MA, González L, Chirinos L, Granados ST, Rodriguez J, Báez R, Remolina Bonilla YA, Núñez Cerrillo G, Archila P, Cuello M, Karachaliou N, Rosell R, Arrieta O; on behalf CLICaP.

Thorac Cancer. 2019 Mar;10(3):508-518. doi: 10.1111/1759-7714.12967. Epub 2019 Jan 31.

33.

Tumor mutational burden as predictive factor of response to immunotherapy.

Gonzalez-Cao M, Viteri S, Karachaliou N, Aguilar A, García-Mosquera JJ, Rosell R.

Transl Lung Cancer Res. 2018 Dec;7(Suppl 4):S358-S361. doi: 10.21037/tlcr.2018.10.03. No abstract available.

34.

Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification.

Bulik-Sullivan B, Busby J, Palmer CD, Davis MJ, Murphy T, Clark A, Busby M, Duke F, Yang A, Young L, Ojo NC, Caldwell K, Abhyankar J, Boucher T, Hart MG, Makarov V, Montpreville VT, Mercier O, Chan TA, Scagliotti G, Bironzo P, Novello S, Karachaliou N, Rosell R, Anderson I, Gabrail N, Hrom J, Limvarapuss C, Choquette K, Spira A, Rousseau R, Voong C, Rizvi NA, Fadel E, Frattini M, Jooss K, Skoberne M, Francis J, Yelensky R.

Nat Biotechnol. 2018 Dec 17. doi: 10.1038/nbt.4313. [Epub ahead of print]

PMID:
30556813
35.

Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins.

Neel DS, Allegakoen DV, Olivas V, Mayekar MK, Hemmati G, Chatterjee N, Blakely CM, McCoach CE, Rotow JK, Le A, Karachaliou N, Rosell R, Riess JW, Nichols R, Doebele RC, Bivona TG.

Cancer Res. 2019 Feb 1;79(3):546-556. doi: 10.1158/0008-5472.CAN-18-1492. Epub 2018 Dec 11.

PMID:
30538120
36.

Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features.

Jiang W, Cai MY, Li SY, Bei JX, Wang F, Hampel H, Ling YH, Frayling IM, Sinicrope FA, Rodriguez-Bigas MA, Dignam JJ, Kerr DJ, Rosell R, Mao M, Li JB, Guo YM, Wu XY, Kong LH, Tang JH, Wu XD, Li CF, Chen JR, Ou QJ, Ye MZ, Guo FM, Han P, Wang QW, Wan DS, Li L, Xu RH, Pan ZZ, Ding PR; Written on behalf of AME Colorectal Cancer Cooperative Group.

Int J Cancer. 2019 May 1;144(9):2161-2168. doi: 10.1002/ijc.32044. Epub 2019 Jan 9.

PMID:
30521064
37.

Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC.

Karachaliou N, Fernandez-Bruno M, Bracht JWP, Rosell R.

Transl Lung Cancer Res. 2018 Dec;7(6):691-702. doi: 10.21037/tlcr.2018.06.08. Review.

38.

Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC).

Karachaliou N, Cardona AF, Bracht JWP, Aldeguer E, Drozdowskyj A, Fernandez-Bruno M, Chaib I, Berenguer J, Santarpia M, Ito M, Codony-Servat J, Rosell R.

EBioMedicine. 2019 Jan;39:207-214. doi: 10.1016/j.ebiom.2018.11.036. Epub 2018 Nov 22.

39.

5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging.

Martínez-Terroba E, Behrens C, Agorreta J, Monsó E, Millares L, Felip E, Rosell R, Ramirez JL, Remirez A, Torre W, Gil-Bazo I, Idoate MA, de-Torres JP, Pio R, Wistuba II, Pajares MJ, Montuenga LM.

Thorax. 2019 Apr;74(4):371-379. doi: 10.1136/thoraxjnl-2018-212194. Epub 2018 Nov 24.

PMID:
30472670
40.

Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer.

Karachaliou N, Bracht JWP, Fernandez Bruno M, Drozdowskyj A, Gimenez Capitan A, Moran T, Carcereny E, Cobo M, Domine M, Chaib I, Ramirez JL, Camps C, Provencio M, Vergnenegre A, Lopez-Vivanco G, Majem M, Massuti B, Rosell R.

J Thorac Oncol. 2019 Feb;14(2):304-310. doi: 10.1016/j.jtho.2018.10.168. Epub 2018 Nov 22.

PMID:
30472259
41.

ARID1A Gene Driver Mutations in Lung Adenocarcinomas.

Karachaliou N, Paulina Bracht JW, Rosell R.

J Thorac Oncol. 2018 Dec;13(12):e255-e257. doi: 10.1016/j.jtho.2018.07.099. No abstract available.

PMID:
30467048
42.

Low CD4/CD8 ratio in classical swine fever postnatal persistent infection generated at 3 weeks after birth.

Bohórquez JA, Wang M, Pérez-Simó M, Vidal E, Rosell R, Ganges L.

Transbound Emerg Dis. 2019 Mar;66(2):752-762. doi: 10.1111/tbed.13080. Epub 2018 Dec 9.

PMID:
30457708
43.

Cancer immunotherapy of patients with HIV infection.

Gonzalez-Cao M, Martinez-Picado J, Karachaliou N, Rosell R, Meyerhans A.

Clin Transl Oncol. 2019 Jun;21(6):713-720. doi: 10.1007/s12094-018-1981-6. Epub 2018 Nov 17. Review.

PMID:
30446984
44.

EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP).

Cardona AF, Rojas L, Zatarain-Barrón ZL, Freitas HC, Granados ST, Castillo O, Oblitas G, Corrales L, Castro CD, Ruiz-Patiño A, Martín C, Pérez MA, González L, Chirinos L, Vargas C, Carranza H, Otero J, Rodriguez J, Rodriguez J, Archila P, Lema M, Acosta Madiedo J, Karachaliu N, Wills B, Pino LE, de Lima V, Rosell R, Arrieta O; CLICaP.

Lung Cancer. 2018 Nov;125:265-272. doi: 10.1016/j.lungcan.2018.10.007. Epub 2018 Oct 9.

PMID:
30429031
45.

LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non-small-cell Lung Cancer.

Seymour L, Le Teuff G, Brambilla E, Shepherd FA, Soria JC, Kratzke R, Graziano S, Douillard JY, Rosell R, Reiman A, Lacas B, Lueza B, Aviel-Ronen S, McLeer A, Le Chevalier T, Pirker R, Filipits M, Dunant A, Pignon JP, Tsao MS; LACE-Bio Steering Committee.

Clin Lung Cancer. 2019 Mar;20(2):66-73.e6. doi: 10.1016/j.cllc.2018.10.001. Epub 2018 Oct 11.

PMID:
30414783
46.

Strategies for first-line immunotherapy in squamous cell lung cancer: are combinations a game changer?

Karachaliou N, Fernandez-Bruno M, Rosell R.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S198-S201. doi: 10.21037/tlcr.2018.07.02. No abstract available.

47.

Inhibition of MEK, a canonical KRAS pathway effector in KRAS mutant NSCLC.

Rosell R, Karachaliou N, Codony-Servat C, Ito M.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S183-S186. doi: 10.21037/tlcr.2018.03.20. No abstract available.

48.

Rhomboids and regulation of receptor tyrosine kinase ligands shedding.

Karachaliou N, Rosell R.

EBioMedicine. 2018 Nov;37:19-20. doi: 10.1016/j.ebiom.2018.09.053. Epub 2018 Oct 6. No abstract available.

49.

EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP).

Ruiz-Patiño A, Castro CD, Ricaurte LM, Cardona AF, Rojas L, Zatarain-Barrón ZL, Wills B, Reguart N, Carranza H, Vargas C, Otero J, Corrales L, Martín C, Archila P, Rodriguez J, Avila J, Bravo M, Pino LE, Rosell R, Arrieta O; Latin-American Consortium for the Investigation of Lung Cancer (CLICaP).

Target Oncol. 2018 Oct;13(5):621-629. doi: 10.1007/s11523-018-0594-x.

PMID:
30284706
50.

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.

Blumenthal GM, Bunn PA Jr, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG.

J Thorac Oncol. 2018 Dec;13(12):1818-1831. doi: 10.1016/j.jtho.2018.09.017. Epub 2018 Sep 27. Review.

PMID:
30268698

Supplemental Content

Loading ...
Support Center